NASDAQ:WVE WAVE Life Sciences (WVE) Stock Price, News & Analysis $5.29 +0.04 (+0.76%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About WAVE Life Sciences Stock (NASDAQ:WVE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get WAVE Life Sciences alerts:Sign Up Key Stats Today's Range$5.27▼$5.4850-Day Range$5.05▼$6.3852-Week Range$5.01▼$21.73Volume2.72 million shsAverage Volume3.23 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$22.53Consensus RatingModerate Buy Company Overview WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines. The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications. Several assets are advancing through preclinical research and clinical trials, and WAVE collaborates with biopharmaceutical partners to co-develop selected candidates and expand the reach of its technology into new disease areas. WAVE’s research and development activities are anchored in its laboratories in Cambridge, Massachusetts, where multidisciplinary teams of chemists, biologists and clinical scientists work to translate novel oligonucleotide designs into development candidates. The company also maintains strategic collaborations and research partnerships in North America and Asia, aiming to accelerate global access to its therapies and support regulatory filings in multiple jurisdictions. Founded in 2015, WAVE Life Sciences has built a leadership team with deep expertise in RNA biology, medicinal chemistry and drug development. The company continues to refine its stereopure oligonucleotide platform to address delivery challenges, improve pharmacokinetics and expand its pipeline across a broad range of genetic and rare diseases.AI Generated. May Contain Errors. Read More WAVE Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreWVE MarketRank™: WAVE Life Sciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 418th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingWAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialWAVE Life Sciences has a consensus price target of $22.53, representing about 325.9% upside from its current price of $5.29.Amount of Analyst CoverageWAVE Life Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about WAVE Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for WAVE Life Sciences are expected to decrease in the coming year, from ($1.11) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of WAVE Life Sciences is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of WAVE Life Sciences is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWAVE Life Sciences has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about WAVE Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.00% of the float of WAVE Life Sciences has been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 7.45.Change versus previous monthShort interest in WAVE Life Sciences has recently decreased by 2.65%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWAVE Life Sciences does not currently pay a dividend.Dividend GrowthWAVE Life Sciences does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment-0.97 News SentimentWAVE Life Sciences has a news sentiment score of -0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.Search InterestOnly 25 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -32% compared to the previous 30 days.MarketBeat Follows6 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,476.00 in company stock.Percentage Held by Insiders24.30% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about WAVE Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WVE Stock News HeadlinesWAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in StockAugust 14, 2026 | insidertrades.comWave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma TakeoverAugust 13, 2026 | 247wallst.comBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwide. The analyst, who called the 2020 crash early, is working with a former NSA codebreaker and Pentagon insider on a new approach to AI stocks ahead of August 31. Investors like Stephen and Keith W. say the tools helped shape their portfolios, though results vary and are not typical.August 22 at 1:00 AM | TradeSmith (Ad)Wave Life Sciences: An Fairly Valued RNA OpportunityAugust 12, 2026 | seekingalpha.comWave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference TranscriptAugust 11, 2026 | seekingalpha.comWave Life Sciences Completes Redomiciliation to DelawareAugust 10, 2026 | finance.yahoo.comWave Life Sciences Announces Completion of Redomiciliation to DelawareAugust 10, 2026 | globenewswire.comDid U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?August 7, 2026 | finance.yahoo.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? WAVE Life Sciences' stock was trading at $17.00 at the beginning of the year. Since then, WVE shares have decreased by 68.9% and is now trading at $5.29. How were WAVE Life Sciences' earnings last quarter? WAVE Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings results on Thursday, July, 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.04. The company had revenue of $2.27 million for the quarter, compared to the consensus estimate of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative trailing twelve-month return on equity of 50.36%. Read the conference call transcript. When did WAVE Life Sciences IPO? WAVE Life Sciences (WVE) raised $102 million in an IPO on Wednesday, November 11th 2015. The company issued 6,375,000 shares at $15.00-$17.00 per share. Who are WAVE Life Sciences' major shareholders? Top institutional investors of WAVE Life Sciences include Newtyn Management LLC (0.11%), Handelsbanken Fonder AB (0.04%), AXQ Capital LP (0.03%) and Headlands Technologies LLC (0.02%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Chandra Vargeese, Paul Bolno, Gregory L Verdine, Kyle Moran, Chris Francis, Heidi L Wagner, Mark Corrigan, Ken Takanashi, Christian O Henry and Adrian Rawcliffe. View institutional ownership trends. How do I buy shares of WAVE Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of WAVE Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings7/30/2026Today8/22/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 WVE's financial health is in the Red zone, according to TradeSmith. WVE has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees240Year Founded2012Price Target and Rating Average Price Target for WAVE Life Sciences$22.53 High Price Target$43.00 Low Price Target$12.00 Potential Upside/Downside+325.9%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$204.38 million Net Margins-309.73% Pretax Margin-309.73% Return on Equity-50.36% Return on Assets-40.06% Debt Debt-to-Equity RatioN/A Current Ratio9.99 Quick Ratio9.99 Sales & Book Value Annual Sales$42.73 million Price / Sales24.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book2.30Miscellaneous Outstanding Shares197,050,000Free Float149,165,000Market Cap$1.04 billion OptionableOptionable Beta-1.26 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:WVE) was last updated on 8/22/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | Sponsored23,281 stocks. Only ONE survived.One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...Monument Traders Alliance | SponsoredSomeone just dumped the biggest gold fund.Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...Behind the Markets | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThese 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAIElon Musk calls it the most disruptive force in history. Sam Altman is reportedly preparing a new venture afte...Stansberry Research | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
